HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).
Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.
The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021.
Cerbios has appointed Francesca Scarpitta as director of the company’s high potency active ingredients (HPAIs) production units.
Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in its building dedicated for high potency active ingredients (HPAIs).
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
